Dyadic International (NASDAQ:DYAI) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Dyadic International (NASDAQ:DYAI) posted its quarterly earnings results on Tuesday. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.03), Morningstar.com reports.

Shares of NASDAQ:DYAI opened at $6.10 on Wednesday. Dyadic International has a 12 month low of $1.40 and a 12 month high of $7.30.

In related news, VP Ronen Tchelet sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $5.87, for a total transaction of $58,700.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 23.90% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of the stock. NEXT Financial Group Inc purchased a new position in Dyadic International during the second quarter valued at approximately $50,000. Acadian Asset Management LLC purchased a new position in Dyadic International in the 2nd quarter worth approximately $50,000. Northern Trust Corp purchased a new position in Dyadic International in the 2nd quarter worth approximately $218,000. Advisor Group Inc. purchased a new position in Dyadic International in the 2nd quarter worth approximately $222,000. Finally, Cedar Brook Financial Partners LLC purchased a new position in Dyadic International in the 2nd quarter worth approximately $314,000. 0.40% of the stock is owned by institutional investors.

Several analysts have recently issued reports on the stock. Noble Financial reissued a “buy” rating and issued a $9.00 price target on shares of Dyadic International in a research report on Monday, July 8th. TheStreet raised shares of Dyadic International from a “d” rating to a “c” rating in a research report on Wednesday, April 17th. Finally, ValuEngine lowered shares of Dyadic International from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.

See Also: New Google Finance Tool and Screening Stocks

Earnings History for Dyadic International (NASDAQ:DYAI)

Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.